1. Signaling Pathways
  2. GPCR/G Protein
  3. CXCR
  4. CXCR4 Isoform


Cat. No. Product Name Effect Purity
  • HY-10046
    Antagonist ≥98.0%
    Plerixafor (AMD 3100) is a selective CXCR4 antagonist with an IC50 of 44 nM.
  • HY-50912
    Plerixafor octahydrochloride
    Antagonist ≥98.0%
    Plerixafor octahydrochloride (AMD3100 octahydrochloride) is a selective CXCR4 antagonist with an IC50 of 44 nM.
  • HY-P0171
    Antagonist 99.03%
    Motixafortide (BKT140 4-fluorobenzoyl) is a novel CXCR4 antagonist with an IC50 vakue of ~1 nM.
  • HY-111793A
    NUCC-390 dihydrochloride
    Agonist 99.59%
    NUCC-390 dihydrochloride is a novel and selective small-molecule CXCR4 receptor agonist.
  • HY-50101A
    Mavorixafor trihydrochloride
    Antagonist 98.69%
    Mavorixafor trihydrochloride (AMD-070 trihydrochloride) is a potent, selective and orally available CXCR4 antagonist, with an IC50 value of 13 nM against CXCR4 125I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC50 of 1 and 9 nM, respectively.
  • HY-147808
    CXCR4 antagonist 7
    CXCR4 antagonist 7 (Compound PARA-B) is a CXCR4 antagonist with the IC50 of 9.3 nM.
  • HY-146053
    CXCR4 modulator-1
    CXCR4 modulator-1 (compound ZINC72372983) is a potent CXCR4 modulator with an EC50 value of 100 nM.
  • HY-146372
    CXCR4 antagonist 5
    CXCR4 antagonist 5 (compound 23) is a highly potent CXCR4 antagonist with an IC50 value of 8.8 nM.
  • HY-101458A
    IT1t dihydrochloride
    Antagonist 99.89%
    IT1t dihydrochloride is a potent CXCR4 antagonist; inhibits CXCL12/CXCR4 interaction with an IC50 of 2.1 nM.
  • HY-N0011
    Baohuoside I
    Inhibitor 99.96%
    Baohuoside I, a flavonoid isolated from Epimedium koreanum Nakai, acts as an inhibitor of CXCR4, downregulates CXCR4 expression, induces apoptosis and shows anti-tumor activity.
  • HY-12488
    Inhibitor 99.73%
    LY2510924 is a potent and selective CXCR4 antagonist; blocks SDF-1 binding to CXCR4 with an IC50 of 0.079 nM.
  • HY-P1682A
    Balixafortide TFA
    Antagonist 98.19%
    Balixafortide TFA (POL6326 TFA) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC50 < 10 nM.
  • HY-19867A
    Burixafor hydrobromide
    Antagonist ≥98.0%
    Burixafor hydrobromide (TG-0054 hydrobromide) is an orally bioavailable and potent antagonist of CXCR4 and a well anti-angiogenic drug that is of potential value in treating choroid neovascularization.
  • HY-15478
    Antagonist ≥98.0%
    WZ811 is an orally active, highly potent competitive antagonist of CXCR4.
  • HY-P1102
    Modulator 99.43%
    TC14012, a serum-stable derivative of T140, is a selective and peptidomimetic CXCR4 antagonist with an IC50 of 19.3 nM.
  • HY-15971
    AMD 3465 hexahydrobromide
    Antagonist ≥98.0%
    AMD 3465 hexahydrobromide (GENZ-644494 hexahydrobromide) is a potent antagonist of CXCR4, inhibits binding of 12G5 mAb and CXCL12AF647 to CXCR4, with IC50s of 0.75 nM and 18 nM in SupT1 cells; AMD 3465 also potently inhibits the replication of X4 HIV strains (IC50: 1-10 nM), but has no effect on CCR5-using (R5) viruses.
  • HY-P1104A
    FC131 TFA
    Antagonist 98.38%
    FC131 TFA is a CXCR4 antagonist, inhibits [125I]-SDF-1 binding to CXCR4, with an IC50 of 4.5 nM.
  • HY-114244
    Antagonist 99.97%
    USL311 is a potent and selective CXCR4 antagonist, with anti-tumor activity.
  • HY-13696
    MSX-122 is an orally active partial antagonist of CXCR4, inhibiting CXCR4/CXCL12 actions, with an IC50 of ∼10 nM.
  • HY-P7061A
    ALX 40-4C Trifluoroacetate
    ALX 40-4C Trifluoroacetate is a small peptide inhibitor of the chemokine receptor CXCR4, inhibits SDF-1 from binding CXCR4 with a Ki of 1 μM, and suppresses the replication of X4 strains of HIV-1; ALX 40-4C Trifluoroacetate also acts as an antagonist of the APJ receptor, with an IC50 of 2.9 μM.
Cat. No. Product Name / Synonyms Species Source